

Republic of the Philippines Department of Health

FOOD AND DRUG ADMINISTRATION ug Administration

FDA ADVISORY No. ____2016 -042

1 8 MAY 2016

TO:

ALL HEALTHCARE PROFESSIONALS AND THE

GENERAL PUBLIC

SUBJECT:

Public Health Warning Against the Use of the Unregistered

Drug Product with Registered Counterpart Brand

"Verorab"

The Food and Drug Administration (FDA) advises the public against the use of the following unregistered drug product with registered counterpart brand "Verorab":











Figure 1. Unregistered drug product with registered counterpart brand "Verorab"

These Verorab anti-rabies vaccines were found to be distributed in the Philippine market without approval of the FDA. Likewise, these were confirmed by the Marketing Authorization Holder (MAH), Sanofi Pasteur, Inc. to be illegally imported. The potency of these vaccines are questionable since these were obtained from unknown sources. Thus, proper handling during shipment is not assured, compromising the safety, efficacy, and quality that can result to treatment failure or even death.

All healthcare professionals and the general public are hereby warned to be vigilant of the abovementioned unregistered drug product with registered counterpart brand. This poses potential danger or injury to the consuming public and the importation, selling, or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009.

In the interest of protecting public health and safety, the Officers of the Field Regulatory Operations Office (FROO) are hereby mandated to exercise their regulatory function pursuant to Section 14 of Republic Act No. 9711.

All establishments and outlets are hereby warned against selling and/or dispensing the above identified drug product. Anyone found selling the said drug product will be penalized.

Likewise, all local government units and law enforcement agencies are requested to ensure that this drug product is not sold or offered for sale in their localities or area of jurisdiction.

All consumers are advised to purchase their medications only from FDA-licensed establishments. Please note that, in addition to inspection of establishments, product evaluation, registration, and testing are measures that the government undertakes to ensure the quality, safety, and efficacy of health products. Please look for the FDA Registration number on the product label. Moreover, please be reminded that drug products registered with FDA Philippines bear in their labels information in English and/or in Filipino for all consumers to understand.

The FDA-registered rabies vaccine, Inactivated Rabies Vaccine (Wistar Strain Rabies) [Verorab] 2.5 IU/ 0.5 mL Powder for Suspension I.D./ I.M. Injection, is manufactured by Sanofi Pasteur SA – 2 avenue Pont Pasteur 6900 Lyon, France, imported by Sanofi Pasteur, Inc. – 4F Feliza Bldg., 108 Rufino St., Legaspi Village, Makati City and distributed by Zuellig Pharma Corporation – Km 14 West Service Road SH cor. Edison Ave., Sun Valley, Parañaque City.

The principal display panel of the label of Inactivated Rabies Vaccine (Wistar Strain Rabies) [Verorab] 2.5 IU/ 0.5 mL Powder for Suspension I.D./ I.M. Injection are in English language only and bears the following:

- 1. FDA-licensed Philippine importer and distributor
- 2. FDA registration number
- 3. Rx symbol
- 4. FDA caution statement on dispensing
- 5. Barcode







Figure 2: Registered Drug Product (Registration Number: BR-220)






Figure 3: Registered Drug Product (Registration Number: BR-514)

Inactivated Rabies Vaccine (Wistar Strain Rabies) [Verorab] 2.5 IU/ 0.5 mL Powder for Suspension I.D./ I.M. Injection is indicated for rabies prevention in subjects exposed to risk of contamination and for infants particularly exposed to the risk of rabies. The said product is available in two packaging presentations: (1) Box of 1 vial + 1 syringe diluent (Registration Number: BR-220), and (2) Box of 5 vials + 5 ampoules diluent (Registration Number: BR-514).

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via report@fda.gov.ph or you may call the telephone number (02)807-8275. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: www.fda.gov.ph/adr-report-new and fill out all the required fields.

Dissemination of the information to all concerned is requested.

MARIA LOURDES C. SANTIAGO, MSc, MM
OIC, Director General

DTN: 20160128114731